- Eurofins CDMO Alphora has integrated custom-built Continuous Flow technology to expand its API manufacturing capabilities.
- The project is supported by advisory services and R&D funding from Canada’s NRC Industrial Research Assistance Program.
Eurofins CDMO Alphora has announced the expansion of its active pharmaceutical ingredient (API) manufacturing capabilities through the integration of custom-built Continuous Flow technology. The initiative is supported by advisory services and research and development funding from the National Research Council of Canada Industrial Research Assistance Program.
The Continuous Flow equipment line was developed in-house by Eurofins CDMO Alphora scientists in collaboration with a local university. The technology is designed to intensify complex manufacturing processes that are difficult to scale using traditional batch methods, offering improved efficiency and scalability.
According to the company, the integration of Continuous Flow technology provides enhanced process control, improved safety, and increased production agility. These features are intended to support more robust and sustainable API manufacturing processes across development and commercial stages.
The expansion is expected to strengthen Eurofins CDMO Alphora’s contract manufacturing capabilities, enabling it to support pharmaceutical partners from early-stage process development through to commercial-scale API production.
The company stated that the addition of Continuous Flow technology reinforces its ability to address technically complex API programs while improving operational efficiency and production performance.
